KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data

Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.